More ANDAs To Be Eligible For Priority Review, Gottlieb Says
US FDA Commissioner says agency has necessary resources to expand priority review pathway even as multiple review cycles for generic applications remain common.
US FDA Commissioner says agency has necessary resources to expand priority review pathway even as multiple review cycles for generic applications remain common.